Study of regorafenib plus envafolimab for advanced GIST with KIT exon 17 mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (regorafenib and envafolimab) for people with advanced gastrointestinal stromal tumors (GIST) that have a specific genetic change (KIT exon 17 mutation) and have stopped responding to standard treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of gastrointestinal stromal tumor (GIST).
- You have at least one tumor that can be measured on a scan (CT or MRI).
- Your GIST has grown or you could not tolerate standard treatments like imatinib, sunitinib, regorafenib, or ripretinib.
- Your tumor has a specific genetic change called KIT exon 17 mutation.
- Your overall health is good enough: adequate blood counts, liver and kidney function, and no active infections or other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Hear when a new Metastatic Gastrointestinal Stromal Tumors (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.